Kiniksa Pharmaceuticals
KNSA
228 hedge funds and large institutions have $2.18B invested in Kiniksa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 76 increasing their positions, 85 reducing their positions, and 34 closing their positions.
3,984% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $1.26M
23% more capital invested
Capital invested by funds: $1.77B → $2.18B (+$410M)
21% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 34
3.79% more ownership
Funds ownership: 95.16% → 98.95% (+3.8%)
2% more funds holding
Funds holding: 224 → 228 (+4)
11% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 85
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
Top Sellers
KNSA Hedge Fund Activity: Q1 2026 in Review
228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2026, worth a combined $2.18B — up 23% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new KNSA positions and 34 closed out — a net gain of 7 holders — while 76 added to existing stakes and 85 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $54.4M sold.
- 228 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2026, up from 224 in Q4 2025.
- Funds reported $2.18B of Kiniksa Pharmaceuticals stock for Q1 2026, up 23% quarter-over-quarter.
- 41 funds opened new Kiniksa Pharmaceuticals positions in Q1 2026 and 34 closed out, a net change of +7 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $230M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2026 was Fairmount Funds Management, an estimated $54.4M sold.
Based on aggregated 13F filings for Q1 2026.